Home » Sumitomo, Protez Conclude Licensing Agreement for SMP-601
Sumitomo, Protez Conclude Licensing Agreement for SMP-601
Sumitomo Pharmaceuticals announced that it has signed a licensing agreement with Protez Pharmaceuticals for SMP-601, Sumitomo's proprietary antibiotic candidate. Founded in 2003 with the aid of BTG, Protez Pharmaceuticals is a U.S. venture company engaged in developing innovative antibiotics to combat drug-resistant and other difficult-to-treat infections.
()a href="http://www.japancorp.net/Article.Asp?Art_ID=10103" target="_blank">Japan Corporate News Network
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
02May
-
07May
-
14May
-
23May
-
30May